53 related articles for article (PubMed ID: 9516940)
1. Interleukin-1alpha synergistic in vivo enhancement of cyclophosphamide- and carboplatin-mediated antitumor activity.
Yu WD; Chang MJ; Trump DL; Johnson CS
Cancer Immunol Immunother; 1997 Aug; 44(6):316-22. PubMed ID: 9298933
[TBL] [Abstract][Full Text] [Related]
2. High exposures to bioactivated cyclophosphamide are related to the occurrence of veno-occlusive disease of the liver following high-dose chemotherapy.
de Jonge ME; Huitema AD; Beijnen JH; Rodenhuis S
Br J Cancer; 2006 May; 94(9):1226-30. PubMed ID: 16622453
[TBL] [Abstract][Full Text] [Related]
3. Increase in the effectiveness of melphalan therapy with progression of MOPC-315 plasmacytoma tumor growth.
Ben-Efraim S; Bocian RC; Mokyr MB; Dray S
Cancer Immunol Immunother; 1983; 15(2):101-7. PubMed ID: 6553510
[TBL] [Abstract][Full Text] [Related]
4. Mechanisms of Lymphoma Clearance Induced by High-Dose Alkylating Agents.
Lossos C; Liu Y; Kolb KE; Christie AL; Van Scoyk A; Prakadan SM; Shigemori K; Stevenson KE; Morrow S; Plana OD; Fraser C; Jones KL; Liu H; Pallasch CP; Modiste R; Nguyen QD; Craig JW; Morgan EA; Vega F; Aster JC; Sarosiek KA; Shalek AK; Hemann MT; Weinstock DM
Cancer Discov; 2019 Jul; 9(7):944-961. PubMed ID: 31040105
[TBL] [Abstract][Full Text] [Related]
5. Adaptive therapy.
Gatenby RA; Silva AS; Gillies RJ; Frieden BR
Cancer Res; 2009 Jun; 69(11):4894-903. PubMed ID: 19487300
[TBL] [Abstract][Full Text] [Related]
6. Hyperthermia and Temperature-Sensitive Nanomaterials for Spatiotemporal Drug Delivery to Solid Tumors.
Amin M; Huang W; Seynhaeve ALB; Ten Hagen TLM
Pharmaceutics; 2020 Oct; 12(11):. PubMed ID: 33105816
[TBL] [Abstract][Full Text] [Related]
7. High-dose chemotherapy with autologous stem cell transplant for breast cancer: what have we learned 25 years later?
Nieto Y; Shpall EJ
Biol Blood Marrow Transplant; 2012 Jan; 18(1):3-5. PubMed ID: 22146617
[No Abstract] [Full Text] [Related]
8. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
9. In vivo/ex vivo and in situ assays used in cancer research: a brief review.
Teicher BA
Toxicol Pathol; 2009 Jan; 37(1):114-22. PubMed ID: 19098118
[TBL] [Abstract][Full Text] [Related]
10. Acute in vivo resistance in high-dose therapy.
Teicher BA; Ara G; Keyes SR; Herbst RS; Frei E
Clin Cancer Res; 1998 Feb; 4(2):483-91. PubMed ID: 9516940
[TBL] [Abstract][Full Text] [Related]
11. Modulation of alkylating agents by etanidazole and Fluosol-DA/carbogen in the FSaIIC fibrosarcoma and EMT6 mammary carcinoma.
Teicher BA; Herman TS; Tanaka J; Eder JP; Holden SA; Bubley G; Coleman CN; Frei E
Cancer Res; 1991 Feb; 51(4):1086-91. PubMed ID: 1825474
[TBL] [Abstract][Full Text] [Related]
12. Transforming growth factor-beta 1 overexpression produces drug resistance in vivo: reversal by decorin.
Teicher BA; Ikebe M; Ara G; Keyes SR; Herbst RS
In Vivo; 1997; 11(6):463-72. PubMed ID: 9509296
[TBL] [Abstract][Full Text] [Related]
13. Combination of N,N',N"-triethylenethiophosphoramide and cyclophosphamide in vitro and in vivo.
Teicher BA; Holden SA; Cucchi CA; Cathcart KN; Korbut TT; Flatow JL; Frei E
Cancer Res; 1988 Jan; 48(1):94-100. PubMed ID: 3121169
[TBL] [Abstract][Full Text] [Related]
14. PEG-hemoglobin: effects on tumor oxygenation and response to chemotherapy.
Teicher BA; Ara G; Herbst R; Takeuchi H; Keyes S; Northey D
In Vivo; 1997; 11(4):301-11. PubMed ID: 9292296
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
